Mouse Monoclonal CGB3 Antibody

The CGB3 antibody targets the beta subunit of human chorionic gonadotropin (hCG), a hormone critical in pregnancy and certain cancers. hCG, composed of alpha and beta subunits, is primarily produced by placental syncytiotrophoblasts during pregnancy to support corpus luteum function and progesterone production. The beta subunit (hCG-β) includes multiple isoforms encoded by genes such as *CGB3*, *CGB5*, and *CGB8*, with CGB3 being a key variant. Antibodies against CGB3 are designed to specifically recognize epitopes unique to this isoform, distinguishing it from closely related hormones like luteinizing hormone (LH), which shares structural similarities. These antibodies are typically monoclonal, generated using recombinant CGB3 proteins or synthetic peptides as immunogens. They are vital tools in diagnostic assays (e.g., ELISA, immunohistochemistry) to detect hCG in pregnancy tests, monitor gestational disorders (e.g., ectopic pregnancy, preeclampsia), or diagnose hCG-secreting tumors (e.g., choriocarcinoma, testicular cancers). Research applications include studying hCG's role in trophoblast invasion, angiogenesis, and cancer progression. Specificity validation is crucial to avoid cross-reactivity with other hCG-β isoforms or LH. Recent studies explore CGB3's potential as a biomarker in oncology, particularly in tracking minimal residual disease or therapeutic responses. Robust CGB3 antibodies thus underpin both clinical diagnostics and experimental studies of hCG-related physiology and pathology.